Abstract
With regards to research animal models related to immune thrombocytopenia (ITP), there is an extensive literature of over 300 publications published since 1959. It appears that many of these models either confirm what has been found in human ITP or, in some instances, are the first to describe a phenomenon related to ITP that is still of relevance today in human medicine. These models will undoubtedly play a significant role in the future research of human ITP particularly related to understanding of the pathogenesis of the disorder and the development of novel therapeutics. This review will highlight some of the major animal models utilized for ITP research and will present a somewhat historical aspect of the subject.
Similar content being viewed by others
References
Stasi R, Evangelista ML, Stipa E et al (2008) Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 99:4–13
Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Eng J Med 346:995–1008
Hou M, Stockelberg D, Kutti J, Wadenvik H (1995) Antibodies against GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 55:307–314
Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mohanty D (2000) Influence of auto-antibody specificities on the clinical course in patients with chronic and acute ITP. Platelets 11:94–98
Fabris F, Scandellari R, Ruzzon E et al (2004) Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 103:4562–4564
Zhou B, Zhao H, Yang RC, Han ZC (2005) Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol/Hematol 54:107–116
Michel M (2009) Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol 82(suppl 71):3–7
Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393
Semple JW, Freedman J (1995) Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Transfusion Med Rev 9:327–338
Semple JW (1998) Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Acta Pædiatr Suppl 424:41–45
Coopamah M, Garvey MB, Freedman J, Semple JW (2003) Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfusion Med Rev 17:69–80
Cooper N, Bussel J (2006) The pathogenesis of immune thrombocytopaenic purpura. Brit J Haematol 133:364–374
Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120:187–193
Ling Y, Cao X, Yu Z, Ruan C (2007) Circulating dendritic cells subsets and CD4 + Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 79:310–316
Liu B, Zhao H, Poon MC et al (2007) Abnormality of CD4(+) CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 78:139–143
Stasi R, Del Poeta G, Stipa E et al (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110:2924–2930
Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 112:1147–1150
Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H (2008) Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 12:1078–1084
Yu J, Heck S, Patel V et al (2008) Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112:1325–1328
Zhang X-L, Peng J, Sun J-Z et al (2009) De novo induction of platelet-specific CD4_CD25_ regulatory T cells from CD4_CD25_ cells in patients with idiopathic thrombocytopenic purpura. Blood 113:2568–2577
You S, Alyanakian M-A, Segovia B et al (2008) Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann NY Acad Sci 1150:300–310
Du Y, Fu Y, Mohan C (2008) Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis. Arch Immunol Ther Exp 56(1):31–40
Mix E, Meyer-Rienecker H, Zettl UK (2008) Animal models of multiple sclerosis for the development and validation of novel therapies—potential and limitations. J Neurol 255(Suppl 6):7–14
Hurvitz WRJ, Dodds-Laffin WJ AI (1973) Immunologically mediated thrombocytopenia in the dog. J Amer Vet Med Assoc 163(3):277–282
Putsche JC, Kohn B (2008) Primary immune-mediated thrombocytopenia in 30 dogs (1997–2003). J Amer Animal Hospital Assoc 44(5):250–257
Hammill D, Helton M (1981) Idiopathic thrombocytopenia in a mare. Mod Vet Pract 62(5):392
Jain NC, Switzer JW (1981) Autoimmune thrombocytopenia in dogs and cats. Vet Clin North Am, Small Anim Pract 11(2):421–434
Williams DA, Maggio-Price L (1984) Canine idiopathic thrombocytopenia: clinical observations and long-term follow-up in 54 cases. J Am Vet Med Assoc 185(6):660–663
Endicott M (2003) Oncologic emergencies. Clin Tech Small Anim Pract 18(2):127–130
Rosti P, Zangaglia O (1955) Research on experimental thrombopenia III. Evaluation of the anti-platelet activity of an immune serum by means of agglutination of sensitized sheep erythrocytes with platelet antigen according to a modified Middlebrook–Dubos technic. Boll Ist Sieroter Milan 34:91–96
Rossolini A, Pieri I, Malandrini F (1960) On the action of cortisone in thrombopenia induced in the guinea pig with heterologous immune serum. Riv Clin Pediatr 65:238–244
Chieffi O, Benedetti PA, Lecchini L, Rossolini A (1964) Action of cortisone on neonatal thrombopenia provoked in the guinea pig with heterologous immune serum. Atti Accad Fisiocrit Siena Med Fis 13(1):463–470
Pieri J, Malandrini F, Puglisi P, Rossolini A (1966) On neonatal thrombopenia in the guinea pig (possible passage of antibodies through the milk. Atti Accad Fisiocrit Siena [Med Fis] 15:293–300
Kalmaz GD, McDonald TP (1981) Effects of antiplatelet serum and thrombopoietin on the percentage of small acetylcholinesterase-positive cells in bone marrow of mice. Exp Hematol 9:1002–1010
McDonald TP, Kalmaz GD (1983) Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. Exp Hematol 11:91–97
Bourebia DE, Najean J, Rosset AM Y (1983) Partial purification of a thrombocytopoiesis stimulating factor present in the serum of thrombocytopenic rats. Acta Haematol 69:249–253
Rolovic Z, Baldini M, Dameshek W (1970) Megakaryocytopoiesis in experimentally induced immune thrombocytopenia. Blood 35:173–188
Nakeff A, Roozendaal KJ (1975) Thrombopoietin activity in mice following immune-induced thrombocytopenia. Acta Haematol 54:340–344
Marosi Z, Krizsa F, Rak K (1976) Thrombocytopoietic serum activity in thrombocytopenia induced by antithrombocytic serum in mice. Haematologia 10:249–253
Odell TT, Murphy JR, Jackson CW (1976) Stimulation of megakaryocytopoiesis by acute thrombocytopenia in rats. Blood 48:765–775
Joshi BC, Jain NC (1977) Experimental immunologic thrombocytopenia in dogs: a study of thrombocytopenia and megakaryocytopoiesis. Res Vet Sci 22:11–17
McDonald TP (1978) A comparison of platelet production in mice made thrombocytopenic by hypoxia and by platelet specific antisera. Brit J Haematol 40:299–309
Levin J, Levin FC, Metcalf D (1980) The effects of acute thrombocytopenia on megakaryocyte-CFC and granulocyte-macrophage-CFC in mice: studies of bone marrow and spleen. Blood 56:274–283
Levin J, Levin FC, Penington DG et al (1981) Measurement of ploidy distribution in megakaryocyte colonies obtained from culture: with studies of the effects of thrombocytopenia. Blood 57:287–297
Ebbe S, Levin J, Miller K et al (1987) Thrombocytopoietic response to immunothrombocytopenia in nude mice. Blood 69:192–198
Stenberg PE, Levin J (1989) Ultrastructural analysis of acute immune thrombocytopenia in mice: dissociation between alterations in megakaryocytes and platelets. J Cell Physiol 141:160–169
Krizsa F, Vezendi K, Borbenyi Z, Varga G, Cserhati I (1982) Effect of sera obtained from thrombocytopenic mice on syngeneic long-term bone marrow cultures. Exp Hematol 10:881–885
Linklater KA (1977) Post-transfusion purpura in a pig. Res Vet Sci 22:257–258
Moore S, Friedman RJ, Singal DP et al (1976) Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb Haemost 35:70–81
Wakisaka G, Yasuna GA, Kuramoto K et al (1964) An experimental study of immune thrombocytopenia induced by quinidine. Arerugi 13:686–689
Ashida SI, Abiko Y (1975) Protective effect of pantethine on experimental thrombocytopenia in the rat. Thromb Diath Haemorrhagica 33:528–539
Kekomaki R, Kauppinen HL, Penttinen K, Myllyla G (1977) Interactions of immune complexes and platelets in rabbits immunized with hapten-carrier conjugates. Acta Pathol Microbiol Scand, Sect C Immunol 85:207–214
Ferguson PW, Anderson JH, Krieger RI (1979) Secondary thrombocytopenia following phenobarbital treatments in a rhesus monkey (Macaca mulatta). Lab Animal Sci 29:94–96
Bloom JC, Blackmer SA, Bugelski PJ et al (1985) Gold-induced immune thrombocytopenia in the dog. Vet Pathol 22:492–499
Reilly MP, Taylor SM, Hartman NK et al (2001) Fc{gamma}RIIA requires human platelet factor 4 and platelet activation through heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model. Blood 98:2442–2447
Reilly MP, McKenzie SE (2002) Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol 9:395–400
Lavergne SN, Trepanier LA (2007) Anti-platelet antibodies in a natural animal model of sulphonamide-associated thrombocytopaenia. Platelets 18:595–604
Giles AR, Hoogedoorn H, Blajchman MA, Hirsh J (1980) The thrombogenicity of prothrombin complex concentrates: II. the effect of thrombocytopenia on in vivo thrombogenicity in rabbits. Thromb Res 17:555–560
Barnhart DD, Gengozian N (1975) Actively induced thrombocytopenia in the marmoset. A possible autoimmune model. Clin Exp Immunol 21:493–500
McDonald TP, Clift R (1976) Mechanism of thrombocytopenia induced in mice by anti-platelet serum. Haemost 5:38–50
Dodds WJ (1977) Animal model: canine and equine immune-mediated thrombocytopenia, and idiopathic thrombocytopenic purpura. Amer J Pathol 86:489–491
Gengozian N, McLaughlin CL (1978) Actively induced platelet-bound IgG associated with thrombocytopenia in the marmoset. Blood 51:1197–1210
Krakowka S, Axthelm MK, Gorham JR (1987) Effects of induced thrombocytopenia on viral invasion of the central nervous system in canine distemper virus infection. J Comp Pathol 97:441–450
Arnott J, Horsewood P, Kelton JG (1987) Measurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia. Blood 69:1294–1299
Mylvaganam R, Sprinz PG, Ahn YS, Harrington WJ (1984) An animal model of alloimmune thrombocytopenia. I. The role of the mononuclear phagocytic system (MPS). Clin Immunol Immunopathol 31:163–170
Dominguez V, Govezensky T, Gevorkian G, Larralde C (2003) Low platelet counts alone do not cause bleeding in an experimental immune thrombocytopenic purpura in mice. Haematologica 88:679–687
Wei H, Ding X, Ren J et al (2008) A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen. J Genet Genom 35:665–671
Newman PJ, Kahn RA, Hines A (1981) Detection and characterization of monoclonal antibodies to platelet membrane proteins. J Cell Biol 90:249–253
McMichael AJ, Rust NA, Pilch JR et al (1981) Monoclonal antibody to human platelet glycoprotein I. I. Immunological studies. Brit J Haematol 49:501–509
Ruan C, Tobelem G, McMichael AJ et al (1981) Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function. Brit J Haematol 49:511–519
Vainchenker W, Deschamps JF, Bastin JM et al (1982) Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood 59:514–521
Di Minno G, Thiagarajan P, Perussia B et al (1983) Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex. Blood 61:140–148
Tetteroo PA, Lansdorp PM, Leeksma OC, von dem Borne AE (1983) Monoclonal antibodies against human platelet glycoprotein IIIa. Brit J Haematol 55:509–522
Colle BS (1984) Report of the working party on hybridoma-derived monoclonal antibodies to platelets. Thromb Haemost 51:169–173
Ciaglowski RE, Martinez J, Ryan TJ et al (1986) Monoclonal antibodies to bovine platelet factor 4: species interactions to platelets and megakaryocytes using indirect immunocytofluorescence. Thromb Res 41:855–865
Prendergast MM, Bradstock KF, Broomhead AF et al (1986) Monoclonal antibody analysis of canine hemopoietic cells. Role of Ia-like and Thy-1 antigens in bone marrow engraftment. Transplantation 41:565–571
Rodriguez-Calvillo M, Gabari I, Duarte M et al (2001) Thrombopenic purpura induced by a monoclonal antibody directed to a 35-kilodalton surface protein (p35) expressed on murine platelets and endothelial cells. Exp Hemato 29:589–595
Burstein SA, Friese P, Downs T, Mei RL (1992) Characteristics of a novel rat anti-mouse platelet monoclonal antibody: application to studies of megakaryocytes. Exp Hematol 20:1170
Nieswandt B, Echtenacher B, Wachs F-P et al (1999) Acute systemic eaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood 94:684–691
Nieswandt B, Bergmeier W, Rackebrandt K et al (2000) Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 96:2520–2527
Crow AR, Song S, Semple JW et al (2001) IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Brit J Haematol 115:679–686
Teeling JL, Jansen-Hendriks T, Kuijpers TE et al (2001) Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98:1095–1099
Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science 291:484–486
Song S, Crow AR, Freedman J et al (2003) Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 101:3708–3713
Song S, Crow AR, Siragam V et al (2005) Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 105:1546–1548
Siragam V, Crow AR, Brinc D et al (2006) Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12:688–692
Leytin V, Sergiy M, Starkey AF et al (2006) Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 133:452–460, Erratum
Crow AR, Song S, Semple JW et al (2007) A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 09:155–158
Tsubakio T, Hamano T, Shintome M et al (1987) Mechanism of increase in platelet count by intravenous gammaglobulin in thrombocytopenic rats. Acta Haematologica Jap 50:1031–1037
Hansen RJ, Balthasar JP (2003) Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharmaceut Sci 92:1206–1215
Siragam V, Brinc D, Crow AR et al (2005) Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 115:155–160
Park-Min KH, Serbina NV, Yang W et al (2007) FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26:67–78
Deng R, Balthasar JP (2007) Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharmaceut Sci 96:25–37
Crow AR, Lazarus AH (2008) The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfusion Med Rev 22:103–116
Anthony RM, Nimmerjahn F, Ashline DJ et al (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373–376
Kaveri SV, Lacroix-Desmazes S, Bayry J (2008) The antiinflammatory IgG. New Engl J Med 359:307–309
Hang LM, Izui S, Dixon FJ (1981) A model of acute lupus and coronary vascular disease with myocardial infraction. J Exp Med 154:216–221
Oyaizu N, Yasumizu R, Miyama-Inaba M et al (1988) A new animal of idiopathic thrombocytopenic purpura. J Exp Med 167:2017–2022
Mizutani H, Furubayashi T, Kurlu A et al (1990) Analyses of thrombocytopenia in idiopathic thrombocytopenic purpura-prone mice by platelet transfer experiments between (NZW X BXSB) F1 and normal mice. Blood 75:1809–1812
Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA (1993) Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F1 mice. Blood 82:837–844
Vanhoorelbeke MK, Deckmyn H, Coutelier J-P (2004) A new model of transient strain-dependent autoimmune thrombocytopenia in mice immunized with rat platelets. Exp Hematol 32:87–94
Musaji A, Cormont F, Thirion G, Cambiaso CL, Coutelier JP (2004) Exacerbation of autoantibody mediated thrombocytopenia purpura by infection with mouse viruses. Blood 104:2102–2106
Musaji A, Meite M, Detalle L et al (2005) Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia. Autoimmune Rev 4:247–252
Alves-Rosa F, Stanganelli C, Cabrera J et al (2000) Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96:2834–2840
Tremblay T, Aubin E, Lemieux R, Bazin R (2007) Picogram doses of lipopolysaccharide exacerbate antibody mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice. Brit J Haematol 139:297–302
Semple JW, Aslam R, Kim M, Speck ER, Freedman J (2007) Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG opsonized platelets. Blood 109:4803–4805
Asahi A, Nishimoto T, Okazaki Y et al (2008) Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. J Clin Invest 118:2939–2949
Ni H, Chen P, Spring CM et al (2006) A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 107:2976–2983
Webster ML, Sayeh E, Crow M et al (2006) Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIb antibodies. Blood 108:943–946
Go RS, Johnston KL, Bruden KC (2007) The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 92(2):283–284
Chow L, Kim M, Speck ER et al. (2009). A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood (in press)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Semple, J.W. Animal models of immune thrombocytopenia (ITP). Ann Hematol 89 (Suppl 1), 37–44 (2010). https://doi.org/10.1007/s00277-009-0882-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-009-0882-8